These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

552 related articles for article (PubMed ID: 18075464)

  • 1. Arg389Gly-beta1-adrenergic receptors determine improvement in left ventricular systolic function in nonischemic cardiomyopathy patients with heart failure after chronic treatment with carvedilol.
    Chen L; Meyers D; Javorsky G; Burstow D; Lolekha P; Lucas M; Semmler AB; Savarimuthu SM; Fong KM; Yang IA; Atherton J; Galbraith AJ; Parsonage WA; Molenaar P
    Pharmacogenet Genomics; 2007 Nov; 17(11):941-9. PubMed ID: 18075464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of beta-adrenergic receptor gene polymorphisms in the long-term effects of beta-blockade with carvedilol in patients with chronic heart failure.
    Metra M; Covolo L; Pezzali N; Zacà V; Bugatti S; Lombardi C; Bettari L; Romeo A; Gelatti U; Giubbini R; Donato F; Dei Cas L
    Cardiovasc Drugs Ther; 2010 Feb; 24(1):49-60. PubMed ID: 20352314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic polymorphisms of beta1 and alpha2C-adrenergic receptors and the influence on left ventricular ejection fraction response to beta-blocker therapy in heart failure.
    Lobmeyer MT; Gong Y; Terra SG; Beitelshees AL; Langaee TY; Pauly DF; Schofield RS; Hamilton KK; Herbert Patterson J; Adams KF; Hill JA; Aranda JM; Johnson JA
    Pharmacogenet Genomics; 2007 Apr; 17(4):277-82. PubMed ID: 17496726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A controlled study of the effects of carvedilol on clinical events, left ventricular function and proinflammatory cytokines levels in patients with dilated cardiomyopathy.
    Tatli E; Kurum T
    Can J Cardiol; 2005 Mar; 21(4):344-8. PubMed ID: 15838561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative efficacy of nebivolol versus carvedilol on left ventricular function and exercise capacity in patients with nonischemic dilated cardiomyopathy. A 12-month study.
    Patrianakos AP; Parthenakis FI; Mavrakis HE; Diakakis GF; Chlouverakis GI; Vardas PE
    Am Heart J; 2005 Nov; 150(5):985. PubMed ID: 16290981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial.
    Jabbour A; Macdonald PS; Keogh AM; Kotlyar E; Mellemkjaer S; Coleman CF; Elsik M; Krum H; Hayward CS
    J Am Coll Cardiol; 2010 Apr; 55(17):1780-7. PubMed ID: 20413026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Carvedilol improves left atrial and left ventricular function and reserve in dilated cardiomyopathy after 1 year of treatment.
    Paraskevaidis I; Farmakis D; Parissis JT; Dodouras T; Filippatos G; Tsiapras D; Kremastinos DT
    J Card Fail; 2007 Mar; 13(2):108-13. PubMed ID: 17395050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Marked improvement in left ventricular ejection fraction during long-term beta-blockade in patients with chronic heart failure: clinical correlates and prognostic significance.
    Metra M; Nodari S; Parrinello G; Giubbini R; Manca C; Dei Cas L
    Am Heart J; 2003 Feb; 145(2):292-9. PubMed ID: 12595847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of dilated cardiomyopathy with carvedilol in children.
    Erdoğan I; Ozer S; Karagöz T; Celiker A; Ozkutlu S; Alehan D
    Turk J Pediatr; 2009; 51(4):354-60. PubMed ID: 19950843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of association between adrenergic receptor genotypes and survival in heart failure patients treated with carvedilol or metoprolol.
    Sehnert AJ; Daniels SE; Elashoff M; Wingrove JA; Burrow CR; Horne B; Muhlestein JB; Donahue M; Liggett SB; Anderson JL; Kraus WE
    J Am Coll Cardiol; 2008 Aug; 52(8):644-51. PubMed ID: 18702968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of beta-adrenergic receptor polymorphisms and progression to heart failure in patients with idiopathic dilated cardiomyopathy.
    Forleo C; Resta N; Sorrentino S; Guida P; Manghisi A; De Luca V; Romito R; Iacoviello M; De Tommasi E; Troisi F; Rizzon B; Guanti G; Rizzon P; Pitzalis MV
    Am J Med; 2004 Oct; 117(7):451-8. PubMed ID: 15464701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human heart beta-adrenoceptors: beta1-adrenoceptor diversification through 'affinity states' and polymorphism.
    Molenaar P; Chen L; Semmler AB; Parsonage WA; Kaumann AJ
    Clin Exp Pharmacol Physiol; 2007 Oct; 34(10):1020-8. PubMed ID: 17714089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of neurohormonal activity after treatment of children in heart failure with carvedilol.
    Giardini A; Formigari R; Bronzetti G; Prandstraller D; Donti A; Bonvicini M; Picchio FM
    Cardiol Young; 2003 Aug; 13(4):333-6. PubMed ID: 14694952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of carvedilol, a vasodilator-beta-blocker, in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group.
    Circulation; 1995 Jul; 92(2):212-8. PubMed ID: 7600653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents.
    Lowes BD; Gilbert EM; Abraham WT; Minobe WA; Larrabee P; Ferguson D; Wolfel EE; Lindenfeld J; Tsvetkova T; Robertson AD; Quaife RA; Bristow MR
    N Engl J Med; 2002 May; 346(18):1357-65. PubMed ID: 11986409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased low-grade inflammation is associated with lack of functional response to carvedilol in patients with systolic heart failure.
    Fragasso G; Spoladore R; Maranta F; Corti A; Lattuada G; Colombo B; Locatelli M; Salerno A; Calori G; Briceno L; Alfieri AB; Perseghin G; Margonato A
    J Cardiovasc Med (Hagerstown); 2013 Jan; 14(1):49-56. PubMed ID: 23018486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of combined versus selective adrenergic blockade on left ventricular and systemic hemodynamics, myocardial substrate preference, and regional perfusion in conscious dogs with dilated cardiomyopathy.
    Nikolaidis LA; Poornima I; Parikh P; Magovern M; Shen YT; Shannon RP
    J Am Coll Cardiol; 2006 May; 47(9):1871-81. PubMed ID: 16682315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myocardial beta-adrenergic receptor density assessed by 11C-CGP12177 PET predicts improvement of cardiac function after carvedilol treatment in patients with idiopathic dilated cardiomyopathy.
    Naya M; Tsukamoto T; Morita K; Katoh C; Nishijima K; Komatsu H; Yamada S; Kuge Y; Tamaki N; Tsutsui H
    J Nucl Med; 2009 Feb; 50(2):220-5. PubMed ID: 19164238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of carvedilol in infants with dilated cardiomyopathy: a preliminary report.
    Gachara N; Prabhakaran S; Srinivas S; Farzana F; Krishnan U; Shah MJ
    Indian Heart J; 2001; 53(1):74-8. PubMed ID: 11456146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of carvedilol on systolic and diastolic left ventricular performance in idiopathic dilated cardiomyopathy or ischemic cardiomyopathy.
    Quaife RA; Gilbert EM; Christian PE; Datz FL; Mealey PC; Volkman K; Olsen SL; Bristow MR
    Am J Cardiol; 1996 Oct; 78(7):779-84. PubMed ID: 8857482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.